Keith W Brown

List of Publications by Year
in descending order

34 papers	1,538 citations	304743 22 h-index	434195 31 g-index
37 all docs	37 docs citations	37 times ranked	2076 citing authors

#	Article	IF	Citations
1	Imprinting mutations in the Beckwithâ€"Wiedemann syndrome suggested by an altered imprinting pattern in the IGF2â€"H19 domain. Human Molecular Genetics, 1995, 4, 2379-2385.	2.9	235
2	Frequent Long-Range Epigenetic Silencing of Protocadherin Gene Clusters on Chromosome 5q31 in Wilms' Tumor. PLoS Genetics, 2009, 5, e1000745.	3.5	129
3	Somatic Allelic Loss at the DCC, APC, nm23-H1 and P53 Tumor Suppressor Gene Loci in Human Prostatic Carcinoma. Journal of Urology, 1994, 151, 1073-1077.	0.4	91
4	Microdissecting the Genetic Events in Nephrogenic Rests and Wilms' Tumor Development. American Journal of Pathology, 1998, 153, 991-1000.	3.8	78
5	Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer. Rna, 2007, 13, 2287-2299.	3.5	71
6	Radioimmunoassay of brain-type creatine kinase-BB isoenzyme in human tissues and in serum of patients with neurological disorders. Journal of the Neurological Sciences, 1980, 47, 241-254.	0.6	70
7	Loss of WT1 function leads to ectopic myogenesis in Wilms' tumour. Nature Genetics, 1998, 18, 15-17.	21.4	69
8	Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. Human Molecular Genetics, 2003, 13, 405-415.	2.9	69
9	Purification, radioimmuno assay, and distribution of human brain 14-3-2 protein (nervous-system) Tj ETQq1 1 0.784314 rgBT /Overloc	2.4	62
10	Germline and somatic abnormalities of chromosome 7 in Wilms' tumor. Cancer Genetics and Cytogenetics, 1994, 77, 93-98.	1.0	54
11	DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochemical Pharmacology, 2012, 83, 858-865.	4.4	49
12	Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells. Molecular Oncology, 2015, 9, 617-627.	4.6	49
13	Antisense WT1 transcription parallels sense mRNA and protein expression in fetal kidney and can elevate protein levelsin vitro. , 1998, 185, 352-359.		45
14	Low frequency of mutations in theWT1 coding region in Wilms' tumor. Genes Chromosomes and Cancer, 1993, 8, 74-79.	2.8	42
15	Hypomethylation and Aberrant Expression of the Glioma Pathogenesis-Related 1 Gene in Wilms Tumors. Neoplasia, 2007, 9, 970-978.	5.3	40
16	Autoregulation of the human WT1 gene promoter. FEBS Letters, 1994, 349, 75-78.	2.8	38
17	A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis. Human Molecular Genetics, 2007, 16, 343-354.	2.9	36
18	Control of epigenetic states by WT1 via regulation of de novo DNA methyltransferase 3A. Human Molecular Genetics, 2013, 22, 74-83.	2.9	36

#	Article	IF	Citations
19	Alteration of the extracellular matrix of cultured human keratinocytes by transformation and during differentiation. International Journal of Cancer, 1985, 35, 799-807.	5.1	32
20	Perilobar Nephrogenic Rests Are Nonobligate Molecular Genetic Precursor Lesions of Insulin-Like Growth Factor-II-Associated Wilms Tumors. Clinical Cancer Research, 2008, 14, 7635-7644.	7.0	30
21	Extracellular matrix components produced by SV40-transformed human epidermal keratinocytes. International Journal of Cancer, 1984, 33, 257-263.	5.1	29
22	The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour. Oncogene, 2003, 22, 1371-1380.	5.9	28
23	The molecular biology of Wilms' tumour. Expert Reviews in Molecular Medicine, 2001, 3, 1-16.	3.9	24
24	Genomeâ€wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma. Molecular Carcinogenesis, 2017, 56, 1290-1301.	2.7	23
25	Frequency and Timing of Loss of Imprinting at 11p13 and 11p15 in Wilms' Tumor Development. Molecular Cancer Research, 2008, 6, 1114-1123.	3.4	20
26	Localization of a novel t(1;7) translocation associated with Wilms' tumor predisposition and skeletal abnormalities. , 1996, 17, 151-155.		19
27	Epigenetic deregulation of GATA3 in neuroblastoma is associated with increased GATA3 protein expression and with poor outcomes. Scientific Reports, 2019, 9, 18934.	3.3	17
28	Characterization of 17.94, a novel anaplastic Wilms' tumor cell line. Cancer Genetics, 2012, 205, 319-326.	0.4	16
29	Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2â€²-deoxycytidine (AZA) in breast cancer cells. Experimental Cell Research, 2013, 319, 2282-2295.	2.6	16
30	Transactivation of the WT1 antisense promoter is unique to the WT1 [+/â^'] isoform. FEBS Letters, 1999, 456, 131-136.	2.8	8
31	MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma. Molecular Carcinogenesis, 2014, 53, 413-420.	2.7	6
32	Low frequency of genetic lesions in Wilms tumors by representational difference analysis. Cancer Genetics and Cytogenetics, 2001, 127, 155-160.	1.0	3
33	The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor. Molecular Oncology, 2022, 16, 630-647.	4.6	3
34	SSCP and incorporation of 7-deaza-2â€²ddGTP into PCR products. Trends in Genetics, 1994, 10, 225.	6.7	0